SYRS (Syros Pharmaceuticals) Total Liabilities : $96.12 Mil (As of Sep. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Syros Pharmaceuticals Total Liabilities?

Syros Pharmaceuticals's Total Liabilities for the quarter that ended in Sep. 2024 was $96.12 Mil.

Syros Pharmaceuticals's quarterly Total Liabilities declined from Mar. 2024 ($119.67 Mil) to Jun. 2024 ($113.07 Mil) and declined from Jun. 2024 ($113.07 Mil) to Sep. 2024 ($96.12 Mil).

Syros Pharmaceuticals's annual Total Liabilities increased from Dec. 2021 ($97.72 Mil) to Dec. 2022 ($116.75 Mil) and increased from Dec. 2022 ($116.75 Mil) to Dec. 2023 ($151.51 Mil).

Syros Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Syros Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syros Pharmaceuticals Total Liabilities Chart

Syros Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

70.79

122.70

97.72

116.75

151.51

Syros Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Liabilities	Get a 7-Day Free Trial															111.49	151.51	119.67	113.07	96.12

Syros Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Syros Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	36.681	+	(53.084	+	61.747
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	151.51

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	168.174	-	16.662
	=	151.51

Syros Pharmaceuticals's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	28.392	+	(57.642	+	10.084
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	96.12

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	84.995	-	-11.123
	=	96.12

Syros Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Syros Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Syros Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syros Pharmaceuticals Inc (NAS:SYRS) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

0LC7:UK 0S90:Germany

Address

35 CambridgePark Drive, 4th Floor, Cambridge, MA, USA, 02140

Website

https://www.syros.com

Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.

Executives

Nancy A Simonian	director, 10 percent owner, officer: President & CEO	C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Gerald E Quirk	officer: Chief Legal Officer	C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
David Roth	officer: Chief Medical Officer	C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Jason Haas	officer: Chief Financial Officer	C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Kristin Stephens	officer: Chief Development Officer	C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Chee Conley	officer: Chief Commercial Officer	C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Srinivas Akkaraju	director	565 EVERETT AVENUE, PALO ALTO CA 94301
Eric R Olson	officer: Chief Scientific Officer	C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, SUITE 300, CAMBRIDGE MA 02139
Timothy Tyson	director	ONE ENTERPRISE, ALISO VIEJO CA 92656
Andrew M. Oh	director	C/O RUBIUS THERAPEUTICS, 325 VASSAR ST., STE. 1A, CAMBRIDGE MA 02139
Deborah Dunsire	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Richard A Young	director	C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE SUITE 300, CAMBRIDGE MA 02139
Sue Gail Eckhardt	director	C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Mark J Alles	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Jeremy P. Springhorn	officer: Chief Business Officer	C/O UNIQUIRE N.V., 113 HARTWELL AVENUE, LEXINGTON MA 02421